TSE:4088
TSE:4088Chemicals

Stronger Medical And Energy Outlook Might Change The Case For Investing In Air Water (TSE:4088)

Air Water Inc. reported its latest quarterly results on 23 December 2025, with analysts ahead of the release expecting earnings per share to exceed prior estimates and revenue to be supported by growth in its medical and energy businesses. Meyka AI’s B+ grade and general buy-oriented stance toward Air Water highlighted growing confidence in the company’s positioning across these expanding sectors. We’ll now examine how optimism around Air Water’s medical and energy growth prospects shapes...
TSE:2726
TSE:2726Specialty Retail

Should PAL Group’s 9-Month Same-Store Sales Streak Shape How Investors View Its Brand Strategy (TSE:2726)?

PAL Group Holdings recently reported a 6.5% year-on-year increase in same-store sales for November, marking the ninth consecutive month of growth driven by a recovery in store traffic and strength in casual brands. The continued outperformance of Discot and 3COINS against this backdrop highlights how key concepts within the portfolio are underpinning the company’s broader sales momentum. We’ll now examine how this sustained same-store sales growth, particularly the rebound in casual brands,...
TSE:8570
TSE:8570Consumer Finance

Assessing AEON Financial Service (TSE:8570)’s Valuation After Profit Surge, Cleaner Credit Book and Digital Investment

AEON Financial Service (TSE:8570) is drawing fresh attention after its AEON Credit Service (Asia) unit reported a 28% jump in nine month profit, alongside cleaner credit books and sustained digital investment. See our latest analysis for AEON Financial Service. The market seems to be catching on to this story, with a 7 day share price return of 10.42 percent and a 1 year total shareholder return of 43.57 percent, which signals that momentum is building rather than fading. If this kind of...
TSE:4587
TSE:4587Biotechs

How Investors May Respond To PeptiDream (TSE:4587) Expanding RNAi Delivery And Advancing Oral IL-17 Autoimmune Program

In December 2025, PeptiDream announced it had reached a preclinical development milestone with Alnylam in their siRNA delivery collaboration, and separately advanced its second oral peptide program, a dual IL-17A/IL-17F macrocyclic inhibitor for autoimmune diseases, into its clinical development portfolio. Together, these updates highlight the breadth of PeptiDream’s PDPS® platform, extending into extrahepatic RNAi delivery and potentially oral alternatives to injectable IL-17...